TX-MARY-KAY
15.2.2024 18:14:28 CET | Business Wire | Press release
Since 2021, Mary Kay Inc. has partnered with the Equal Rights Trust (ERT), an organization whose mission is to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. supported new research focused on understanding and addressing the discriminatory impacts of artificial intelligence (AI) and its impacts on gender equality, and the development of a new “equality by design approach.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215911706/en/
“Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. (Photo: Mary Kay Inc.)
The initiative culminated with the recent launch of a new set of legal standards – the Principles on Equality by Design in Algorithmic Decision-Making – developed by the Equal Rights Trust and endorsed by a group of leading international equality organizations. The Principles elaborate why national governments and businesses must adopt such an approach and provide detailed guidance for its implementation.
Jim Fitzgerald, Director of Equal Rights Trust, just released an article highlighting the rapid advancements and transformative potential of artificial intelligence while also warning about adverse impacts and discriminatory threats unregulated algorithmic systems could pose.
- Read Jim Fitzgerald’s article titled Equality by Design: A Model for Managing Discriminatory Risks of AI here.
Statements from Jim Fitzgerald, Director of Equal Rights Trust and Melinda Foster Sellers, Chief People Officer at Mary Kay Inc., can be found below:
- “Over the last three years, Mary Kay has supported our research, analysis, and consultation on algorithmic discrimination, and enabled us to develop the Principles on Equality by Design,” said Jim Fitzgerald, Director of the Equal Rights Trust. “Now, Mary Kay is working with us as we move into the next phase: a collaborative effort to develop practical guidance for business on how to adopt the equality by design approach. In doing so, it is taking the next step in a journey which started with strong internal equality and non-discrimination policies, moved to collaboration with and support for us and other actors in this field, and is now focused on incubating and piloting best practice. In this journey, Mary Kay is helping to model how businesses can play an active role in developing improved approaches to eliminating discrimination and advancing equality.”
- "At Mary Kay, we recognize the profound impact that AI has on shaping the future of business and society,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. “Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers. This partnership reflects our enduring mission to empower women and promote equality in every sphere."
About Equal Rights Trust
The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this, it works in partnership to provide expert support to those on the frontlines of the fight against discrimination, enabling them to press for the development, adoption, and implementation of equality law, and to use the law effectively. Since 2007, the Trust has supported equality activists in more than 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly known as Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215911706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
